Travere Therapeutics is a prominent biotechnology company that focuses on creating treatments for rare diseases. With a market capitalization of approximately $4.01 billion, the company directs its efforts toward conditions with significant unmet medical needs, particularly rare kidney diseases. Its stock is currently trading at $43.14 per share.
On June 2, 2026, analyst firm H.C. Wainwright confirmed its positive outlook on Travere Therapeutics by restating its "Buy" rating. A "Buy" rating suggests that the analyst believes the stock is a good investment. The firm also increased its price target to $67.00 from $57.00, indicating it expects the stock's value to rise.
This confidence appears linked to a major new partnership. As highlighted by Reuters, Travere Therapeutics entered a licensing agreement with Everest Medicines for an experimental kidney disease drug. This deal is potentially worth up to $1.14 billion, representing a significant strategic move for the company to expand its treatment offerings.
The agreement gives Travere Therapeutics exclusive rights to develop and sell the drug civorebrutinib in most markets outside of Asia, as reported by Gurufocus. CEO Eric Dube stated the drug is a "strategic and complementary addition" to the company's portfolio, aiming to address the needs of patients with rare immune-mediated kidney diseases.
Despite the positive analyst view, Travere Therapeutics stock saw a daily decline of 4.22%, closing at $43.14. The stock's price has moved between a 52-week low of $13.88 and a 52-week high of $48.61. This range shows the stock's performance and price fluctuations over the past year.
